期刊文献+

FasL基因-844T/C单核苷酸多态性与浙江地区食管鳞癌易感性关系的研究

FasL gene-844T/C mutation in relation to susceptibility of esophageal cancer in Zhejiang Province
暂未订购
导出
摘要 目的:研究FasL基因启动子区-844T/C单核苷酸多态性(SNP)与食管鳞癌易感性的关系。方法提取248例食管鳞癌患者(患者组)和297例健康体检者(对照组)外周血基因组DNA,以PCR-RFLP检测FasL-844T/CSNP。分析、比较两组该位点SNP的表达差异。结果食管鳞癌患者与健康体检者的FasL基因启动子区-844位点基因型分布差异有统计学意义(P<0.01)。以TT基因型为对照,TC基因型不增加食管鳞癌患病风险(P>0.05),而CC基因型则显著减少食管鳞癌患病风险(调整后OR=0.425,95%CI=0.255-0.708,P<0.01)。以T等位基因为对照,C等位基因显著减少食管鳞癌患病风险(调整后OR=0.597,95%CI=0.460-0.776,P<0.01)。结论在浙江地区人群中FasL基因-844T/CSNP与食管鳞癌的易感性有关。 Objective To explore the relationship between FasL gene- 844T/C single nucleotide polymorphism (SNP)in promoter and susceptibility of esophageal cancer in Zhejiang Province. Methods The clinical data of 248 patients with esophageal squamous cellcarcinoma admitted in Zhejiang Cancer Hospital from January 2008 to October 2011 were col ected and 297 healthy individuals were selected as normal controls. Genomic DNA was extracted from peripheral whole blood. PCR- RFLP technique was carried out to detect FasL- 844T/C SNP. X2 test and logistic regression was carried out for analysis. Results There was significant difference in genotypes of FasL gene promoter - 844 locus between patients and controls (P〈0.05). CC genotype significantly reduced the prevalence of esophageal squamous cellcarcinoma risk(adjusted OR =0.425, 95%CI 0.255~0.708, P〈0.01). Compared to T al ele, C al ele significantly reduced the prevalence of esophageal squamous cell car-cinoma risk (adjusted OR=0.597, 95%CI 0.460~0.776, P〈0.01). Conclusion FasL gene- 844T/C SNP is associated with the occurrence of esophageal squamous cellcarcinoma in population of Zhejiang Province.
出处 《浙江医学》 CAS 2013年第20期1791-1794,1801,共5页 Zhejiang Medical Journal
基金 2013年浙江医学高等专科学校科研基金 2012年浙江省自然科学基金(LQ12H16001)
关键词 FASL基因 单核苷酸多态性 食管癌 FasL gene SNP Esophageal cancer
  • 相关文献

参考文献19

  • 1Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer[J]. Nature, 2001,411(6835):342-348.
  • 2Wajant H. The Fas signaling pathway: more than a paradigm [J]. Science, 2002, 296(5573): 1635-1636.
  • 3Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/en- hancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients [J]. J Immunol, 2003, 170(1):132-138.
  • 4Gratas C, Tohma Y, Barnas C, et al. Up-regulation of Fas (APO- 1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer[J]. Cancer Res, 1998, 58(10):2057-2062.
  • 5Lee W C, Yu M C, Chen M F. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy[J]. World J Surg, 2004, 28(8):792-796.
  • 6Korkolopoulou P, Saetta A A, Levidou G, et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications[J]. Histopathology, 2007, 51(2): 150- 156.
  • 7Chen L, Park S M, Tumanov A V, et al. CD95 promotes tumour growth [J]. Nature, 2010, 465(7297):492-496.
  • 8Bennett M W, O'Connell J attack in vivo: apoptotic cytes associated with esophageal carcinoma[J] O'Sullivan G C, et al. The Fas counter- depletion of tumor-infiltrating lympho- Fas ligand expression by human J Immunol, 1998, 160(11):5669-5675.
  • 9Sun T, Zhou Y, Li H, et al. FasL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer[J]. J Exp Med, 2005, 202(7):967-974.
  • 10Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FasL contribute to risk of lung cancer[J]. J Med Genet, 2005, 6(42):479-484.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部